You are here

  • Home
  • Archive
  • Volume 9, Issue 12
  • Factors associated with the clinical outcome of patients with relapsed/refractory CD19+ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy

Article metrics

Article menu
Letter
Factors associated with the clinical outcome of patients with relapsed/refractory CD19+ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy

 

Online download statistics by month:

Online download statistics by month: December 2021 to January 2026

AbstractFullPdf
Dec 20210637166
Jan 2022021263
Feb 2022013757
Mar 20220150113
Apr 202207532
May 202207441
Jun 202208328
Jul 202206322
Aug 202204811
Sep 202205526
Oct 202208433
Nov 202203432
Dec 202203111
Jan 202304525
Feb 202304427
Mar 202303523
Apr 202302715
May 202302921
Jun 202302920
Jul 202303314
Aug 20230386
Sep 202302714
Oct 202303923
Nov 202305220
Dec 202305016
Jan 202404015
Feb 202405322
Mar 202404116
Apr 202403417
May 202403718
Jun 202403417
Jul 202403413
Aug 202401412
Sep 202403719
Oct 202403922
Nov 202403016
Dec 202405221
Jan 202505030
Feb 202503719
Mar 202504028
Apr 202504417
May 202504119
Jun 20250399
Jul 2025010
Jan 2026001
Total028281190